Search

Displaying results 4241 - 4250 of 9694 in total
  1. Drug

    HOV-12020

    go.drugbank.com/drugs/DB17976
    Investigational

    HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).[L47271]

  2. Drug

    Briquilimab

    go.drugbank.com/drugs/DB18136
    Investigational

    Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

  3. Drug

    ATX-01

    go.drugbank.com/drugs/DB18141
    Investigational

    ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).

  4. Drug

    MTL-CEBPA

    go.drugbank.com/drugs/DB18143
    Investigational

    MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.

  5. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  6. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  7. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  8. Drug

    LYT-200

    go.drugbank.com/drugs/DB18179
    Investigational

    LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

  9. Drug

    ATI-1013

    go.drugbank.com/drugs/DB18185
    Investigational

    ATI-1013 is a fully human nicotine-specific monoclonal antibody.

  10. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.